Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAIN: Tarloxotinib in Advanced Solid Tumors
NCT03805841Phase 2Terminated
- Sponsor
- Rain Oncology Inc.
- Start
- Mar 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tarloxotinib in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Rain Oncology Inc.. Started Mar 2019; status: terminated.
02
Drugs
tarloxotinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT03805841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805841.